 DUBLIN, July 29, 2021 PRNewswire -- Encouraging Phase I safety and tolerability results of CCH as a nonsurgical treatment of plantar fibromatosis Research to continue to Phase II; retreatment phase also is ongoing in eligible patients Endo International plc NASDAQ:ENDP announced today initial results from a Phase I study EN3835105 evaluating collagenase clostridium histolyticum CCH for the treatment of plantar fibromatosis. The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National, in Denver, July 29August 1. 